Last reviewed · How we verify
Stop ACA
At a glance
| Generic name | Stop ACA |
|---|---|
| Sponsor | French Innovative Leukemia Organisation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE2)
- Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Stop ACA CI brief — competitive landscape report
- Stop ACA updates RSS · CI watch RSS
- French Innovative Leukemia Organisation portfolio CI